NCT01757639 - Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2012

Primary Completion Date

December 31, 2016

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic SyndromePreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid LeukemiaSecondary Myelodysplastic Syndrome

Interventions

BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (9)

10032

Columbia University/Herbert Irving Cancer Center, New York

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27710

Duke University Medical Center, Durham

63110

Washington University School of Medicine, St Louis

75061

Texas Oncology at Baylor Irving Cancer Center, Irving

75246

Baylor University Medical Center, Dallas

06520

Yale University, New Haven

06473

Yale-New Haven Hospital North Haven Medical Center, North Haven

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH